Unknown

Dataset Information

0

Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.


ABSTRACT: Ovarian cancer remains a major cause of cancer mortality in women, with only limited understanding of disease aetiology at the molecular level. Granulocyte colony-stimulating factor (G-CSF) is a key regulator of both normal and emergency haematopoiesis, and is used clinically to aid haematopoietic recovery following ablative therapies for a variety of solid tumours including ovarian cancer.The expression of G-CSF and its receptor, G-CSFR, was examined in primary ovarian cancer samples and a panel of ovarian cancer cell lines, and the effects of G-CSF treatment on proliferation, migration and survival were determined.G-CSFR was predominantly expressed in high-grade serous ovarian epithelial tumour samples and a subset of ovarian cancer cell lines. Stimulation of G-CSFR-expressing ovarian epithelial cancer cells with G-CSF led to increased migration and survival, including against chemotherapy-induced apoptosis. The effects of G-CSF were mediated by signalling via the downstream JAK2/STAT3 pathway.This study suggests that G-CSF has the potential to impact on ovarian cancer pathogenesis, and that G-CSFR expression status should be considered in determining appropriate therapy.

SUBMITTER: Kumar J 

PROVIDER: S-EPMC3887286 | biostudies-other | 2014 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.

Kumar J J   Fraser F W FW   Riley C C   Ahmed N N   McCulloch D R DR   Ward A C AC  

British journal of cancer 20131112 1


<h4>Background</h4>Ovarian cancer remains a major cause of cancer mortality in women, with only limited understanding of disease aetiology at the molecular level. Granulocyte colony-stimulating factor (G-CSF) is a key regulator of both normal and emergency haematopoiesis, and is used clinically to aid haematopoietic recovery following ablative therapies for a variety of solid tumours including ovarian cancer.<h4>Methods</h4>The expression of G-CSF and its receptor, G-CSFR, was examined in primar  ...[more]

Similar Datasets

| S-EPMC6612046 | biostudies-literature
| S-EPMC5706816 | biostudies-other
| S-EPMC2628622 | biostudies-literature
| S-EPMC5501605 | biostudies-literature
| S-EPMC4366643 | biostudies-literature
| S-EPMC7300325 | biostudies-literature
| S-EPMC5684440 | biostudies-literature
| S-EPMC8076515 | biostudies-literature
| S-EPMC5766965 | biostudies-literature
| S-EPMC2700333 | biostudies-literature